Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633 1634 1651
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18025719 | DUAL-AAV VECTOR DELIVERY OF PCDH15 AND USES THEREOF | Final Rejection | President and Fellows of Harvard College |
| 17640281 | CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18266689 | DIFFUSION GRADIENT ASSAY FOR ANTI-CD3-CONTAINING MOLECULES | Non-Final OA | AMGEN INC. |
| 16906937 | METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELLS BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION | Final Rejection | Hoffmann-La Roche Inc. |
| 18017139 | M13 BACTERIOPHAGE WITH A HIGH CYSTEINE CONTENT AND GENETICALLY ENGINEERABLE HYDROGELS | Non-Final OA | Massachusetts Institute of Technology |
| 18182377 | METHOD FOR BUILDING CO-CULTURE MODEL FOR CACO-2/RAW-264.7 CELLS INDUCED BY LIPOPOLYSACCHARIDES AND APPLICATION OF CO-CULTURE MODEL | Final Rejection | ZHEJIANG UNIVERSITY OF TECHNOLOGY |
| 19206692 | METHODS, APPARATUSES AND SYSTEMS FOR INSTILLING STEM CELLS AND PHARMACEUTICALS INTO THE HUMAN VENTRICULAR SYSTEM | Final Rejection | Regeneration Biomedical, Inc. |
| 17344125 | METHODS, APPARATUSES AND SYSTEMS FOR INSTILLING STEM CELLS AND PHARMACEUTICALS INTO THE HUMAN VENTRICULAR SYSTEM | Non-Final OA | Regeneration Biomedical, Inc. |
| 19182523 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | Non-Final OA | FUJIFILM Cellular Dynamics, Inc. |
| 18042037 | CONSUMABLE TISSUE-LIKE STRUCTURE GENERATED WITH MUSCLE CELLS GROWN ON EDIBLE HOLLOW FIBERS | Non-Final OA | Merck Patent GmbH |
| 18662599 | ALIGNMENT OF CELLS IN ENGINEERED TISSUES | Non-Final OA | Regents of the University of Minnesota |
| 17756116 | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF MSC CELLS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18178736 | METHODS AND MICROFLUIDIC DEVICE FOR PRODUCING EXTRACELLULAR VESICLES | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18955455 | METHODS OF RECOMBINANT ADENO-ASSOCIATED VIRUS KIDNEY ADMINISTRATION | Non-Final OA | ASKBIO INC. |
| 17798719 | CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Final Rejection | Sichuan University |
| 17354281 | METHODS AND COMPOSITIONS FOR CULTIVATING PLURIPOTENT CELL SUSPENSIONS | Non-Final OA | Life Technologies Corporation |
| 17614934 | THERAPEUTIC B-CELLS ENGINEERED TO EXPRESS BISPECIFIC T CELL ENGAGER ANTIBODIES | Final Rejection | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18673148 | FUNCTIONALIZED WELL PLATE, METHODS OF PREPARATION AND USE THEREOF | Non-Final OA | BRUKER CELLULAR ANALYSIS, INC. |
| 17276213 | VECTORS EXPRESSING COLOR AND SELECTABLE MARKERS | Final Rejection | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18425997 | SDC-2 EXOSOME COMPOSITIONS AND METHODS OF ISOLATION AND USE | Non-Final OA | Orbsen Therapeutics Limited |
| 17757069 | MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Final Rejection | EDITAS MEDICINE, INC. |
| 17632723 | COMPOSITIONS AND METHODS OF TREATING VASCULAR DISEASES | Non-Final OA | Astellas Institute for Regenerative Medicine |
| 18238509 | MODELS AND METHODS FOR RAPID SCREENING OF THE EFFICACY OF IMMUNOREGULATING DRUGS | Non-Final OA | Shanghai Lide Biotech Co., Ltd. |
| 17550311 | METHODS AND REAGENTS FOR CHARACTERIZING CAR T CELLS FOR THERAPIES | Final Rejection | Allogene Therapeutics, Inc. |
| 18259687 | METHOD FOR PRODUCING REGENERATED T CELL VIA IPS CELL | Non-Final OA | KOTAI BIOTECHNOLOGIES, INC. |
| 18062873 | COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS | Non-Final OA | A2 Biotherapeutics, Inc. |
| 16927304 | TROPIC CELL BASED VIROTHERAPY FOR THE TREATMENT OF CANCER | Non-Final OA | UNIVERSITY OF ALABAMA AT BIRMINGHAM |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy